Atai life sciences announces launch of initial public offering

Berlin, june 11, 2021 (globe newswire) -- atai life sciences b.v. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. all common shares to be sold in the proposed offering will be sold by atai. the underwriters of the offering will have a 30-day option to purchase up to an additional 2,142,900 common shares at the initial public offering price, less the underwriting discounts and commissions. the initial public offering price is expected to be between $13.00 and $15.00 per common share. atai has applied to list its common shares on the nasdaq global market under the ticker symbol “atai.”
ATAI Ratings Summary
ATAI Quant Ranking